These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29146518)

  • 1. Fixed-dose combinations: a potential means to boost drug development for selected drugs.
    Oo C; Sy SKB
    Drug Discov Today; 2018 Mar; 23(3):457-459. PubMed ID: 29146518
    [No Abstract]   [Full Text] [Related]  

  • 2. Polypharmacology in a single drug: multitarget drugs.
    Bolognesi ML
    Curr Med Chem; 2013; 20(13):1639-45. PubMed ID: 23410164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Learning lessons from drugs that have recently entered the market.
    Teague SJ
    Drug Discov Today; 2011 May; 16(9-10):398-411. PubMed ID: 21414418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The animal rule: The role of clinical pharmacology in determining an effective dose in humans.
    Bergman KL
    Clin Pharmacol Ther; 2015 Oct; 98(4):365-8. PubMed ID: 26082064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wrong questions, wrong answers? Are we getting the drugs we need?
    Lipworth WL; Kerridge IH; Day RO
    Clin Pharmacol Ther; 2012 Mar; 91(3):367-9. PubMed ID: 22343808
    [No Abstract]   [Full Text] [Related]  

  • 6. [For an optimal use of fixed drug combinations].
    Bouvenot G; Sassard J; Montastruc JL
    Therapie; 2017 Dec; 72(6):665-668. PubMed ID: 28939009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Giving failed drugs a fresh chance: a new direction for nanoparticle drug delivery.
    Wang AZ
    Expert Rev Med Devices; 2012 Sep; 9(5):445-7. PubMed ID: 23116068
    [No Abstract]   [Full Text] [Related]  

  • 8. Is the pharmaceutical industry's preoccupation with the monotherapy drug model stifling the development of effective new drug therapies?
    Cock IE
    Inflammopharmacology; 2018 Jun; 26(3):861-879. PubMed ID: 29736688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic applications of click chemistry for pharmaceutical drug discovery and drug delivery.
    Meghani NM; Amin HH; Lee BJ
    Drug Discov Today; 2017 Nov; 22(11):1604-1619. PubMed ID: 28754291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of endogenous roles of transporters for drug discovery: hitchhiking and metabolite-likeness.
    Kell DB
    Nat Rev Drug Discov; 2016 Feb; 15(2):143. PubMed ID: 26837595
    [No Abstract]   [Full Text] [Related]  

  • 11. Fixed combination drug therapy.
    Shenfield GM
    Drugs; 1982 Jun; 23(6):462-80. PubMed ID: 7049658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of engineered therapeutics and medication.
    Wang DA
    Pharm Res; 2011 Jun; 28(6):1237-40. PubMed ID: 21491147
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug discovery beyond the rule of 5 - Opportunities and challenges.
    Doak BC; Kihlberg J
    Expert Opin Drug Discov; 2017 Feb; 12(2):115-119. PubMed ID: 27883294
    [No Abstract]   [Full Text] [Related]  

  • 14. Report of a workshop on fixed-ratio drug combinations.
    Dengler HJ; Lasagna L
    Eur J Clin Pharmacol; 1975 Feb; 8(2):149-54. PubMed ID: 823031
    [No Abstract]   [Full Text] [Related]  

  • 15. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
    [No Abstract]   [Full Text] [Related]  

  • 16. Identifying compound efficacy targets in phenotypic drug discovery.
    Schirle M; Jenkins JL
    Drug Discov Today; 2016 Jan; 21(1):82-89. PubMed ID: 26272035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies.
    Bauer RA
    Drug Discov Today; 2015 Sep; 20(9):1061-73. PubMed ID: 26002380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failed Pediatric Drug Development Trials.
    Momper JD; Mulugeta Y; Burckart GJ
    Clin Pharmacol Ther; 2015 Sep; 98(3):245-51. PubMed ID: 25963725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of drug-target residence time.
    Zhang R; Monsma F
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):488-96. PubMed ID: 19562645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemistry-enabled drug delivery (prodrugs): recent progress and challenges.
    Clas SD; Sanchez RI; Nofsinger R
    Drug Discov Today; 2014 Jan; 19(1):79-87. PubMed ID: 23993918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.